Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) recently announced that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold Pharmaceuticals' small molecule hypoxia-targeted drug. TH-302 is currently being investigated in a global Phase 3 clinical trial in patients with soft tissue sarcoma, a randomized Phase 2 trial in patients with advanced pancreatic cancer from which top-line results are expected in February, as well as additional clinical studies in other solid tumors and hematological malignancies.

Under the terms of the agreement, Merck will receive co-development rights, exclusive global commercialization rights and will provide Threshold Pharmaceuticals an option to co-commercialize the therapeutic in the United States. In exchange, Threshold Pharmaceuticals will receive an upfront payment of $25 million and could receive up to $35 million in additional development milestones during 2012. Threshold Pharmaceuticals, Inc. is also eligible to receive a $20 million milestone payment based on positive results from its randomized Phase 2 trial in pancreatic cancer. Total potential milestone payments are $525 million, comprised of $280 million in regulatory and development milestones and $245 million in sales-based milestones.

Threshold Pharmaceuticals, a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. The products from Threshold Pharmaceuticals include TH-302, a novel drug candidate which is in Phase 1, Phase 1/2, and Phase 2 clinical trials for cancer. Threshold Pharmaceuticals has a license agreement with Eleison Pharmaceuticals, Inc. to develop and commercialize glufosfamide for the treatment of cancer in humans and animals. Threshold Pharmaceuticals was founded in 2001 and is headquartered in Redwood City, California.

For more information about Threshold Pharmaceuticals, please visit: www.thresholdpharm.com

Read full article at: http://bestotc.com/19794/stock-alerts/thld-che-mjgcf-tyc-cvg-stock-in-re...

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

********************************

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOtc.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://bestotc.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold BestOTC.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.